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Table
Factors Affecting the Post-transplant Progression Free Survival
PFS (months)
mean SD
95% CI P
Sex
Female
Male
26.1  2.6
20.3  2.2
21.0-31.2
16.0-24.5
.135
Subtype
Light chain
Others
30.6  3.0
20.3  1.9
24.7-36.5
16.5-24.1
.008
International Staging System 27.2  2.8 21.7-32.7 .047
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Introduction: High dose therapy followed by autologous
hematopoietic stem cell transplantation (ASCT) has an
established role in the treatment of patients with multiple
myeloma (MM). The CR rate, an indicator for progression-
free and overall survival (PFS; OS) observed after the most
commonly used conditioning regimen Mel200 (Melphalan
200mg/m2) is between 10-35%. The objective of our trial is to
assess whether conditioning with a combination of PK-
directed Busulfan (Bu), Mel and Bortezomib (Btz) is safe and
can improve CR rates in patients with MM.
Methods: Patients aged 18-72 with MM, who had received
less than one year of prior myeloma-directed therapy and
were eligible for ASCT were assigned to receive PK-directed
i.v. Bu, i.v. Mel and i.v. Btz as per Fig. 1. Subsequent con-
solidative or maintenance therapy was left to investigator’s
choice. Primary outcome was CR rate assessed on D +100
post ASCT as per IMWG criteria. Secondary outcomes are
overall response rate (ORR), toxicities, PFS and OS. The trial is
registered at clinicaltrials.gov (NCT01605032).
Results: To date, 18 patients have been treated (median age
61 (range 44-70), 61% male, 17% with ISS stage 3; median
number of prior regimens 1 (range 1-3); prior bortezomib
94%). For the 12 evaluable patients the median days to ANC
>/¼0.5 x 109/L and platelet count >/¼30 x 109/L were 11
(range 10-13) and 17 (11-29), respectively. Themost common
non-hematological toxicities (100%) were alopecia, oral
mucositis (62% G3), dysphagia (85% G3), as well as electrolyte
abnormalities (62% G3). Other common toxicities were
nausea (92%, all G1/2), diarrhea (84% G1/2, 15% G3), while
84% of patients developed fully reversible transaminitis (15%
G3). Less common G3 toxicities included delirium (8%), co-
litis (8%), skin infection (15%; zoster & skin abscess, 1 each),
other infections (31%), and engraftment syndrome (8%). No
patient developed sinusoidal obstruction syndrome of the
liver. Response assessment was available for 11 patients: 1
achieved a stringent CR (9.1%), 5 VGPR (45.5%), and 5 PR
(45.5%), resulting in a 100% ORR. After a median follow up of
5.2 months (range 1-18) all patients are alive and no patient
has relapsed. The trial is ongoing.
Conclusion: PK directed i.v. Bu in combination with Mel and
Btz (BuMelBtz) is an effective and safe conditioning regimen
for patients with MM. Further evaluation is warranted.Fig. 1. Treatment Schema
Following a Busulfan (Bu) test dose (0.8mg/kg) prior to the ﬁrst treatment
dose, intravenous (i.v.) Bu is given 4 times daily as 3-hour infusion from day
(D) -6 to -3 to target a total AUC of 20,000 uMxmin (PK-directed Busulan); i.v.
Melphalan (Mel; 140mg/m2) is given on D-2, and i.v. Bortezomib (BTZ; 1.4mg/
m2) on D-6, -4, +1 and +4.127
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Despite the improvements in response rates in multiple
myeloma during the last decade, relapses still remain as a
problem. Aim of this study was to evaluate the factors
associated with response and the length of progression free
survival (PFS) following autologous hematopoietic cell
transplantation (ASCT). Out of 113 consecutive patients with
newly diagnosed MM, 43 % and 19% achieved Post-ASCT
complete remission (CR) or very good partial remission
(VGPR) respectively. Post-ASCT response status was signiﬁ-
cantly associated with female sex, light chain myeloma, b-2
microglobulin (3.5mg/L) and pre-ASCT response status.
Multiparameter ﬂow cytometry detected abnormal plasma
cells (APC) in the harvests of 9.7% of patients. Higher pro-
portion of patients who had contaminated harvests were at
<VGPR status duringmobilization compared to patients who
did not have contamination (73% vs 53%; p¼.088). Presence
of APC in the harvests compared to those lacking APC was
signiﬁcantly associated with progression at 12 months after
ASCT (75% vs 36%; p¼.039). The median PFS was 13 (2-45)
months after a median follow-up of 33 (7-148) months.ISS1
ISS2
ISS3
24.2  2.9
15.9  2.7
18.6-29.9
10.7-21.1
Cytogenetics
del13q negative
del13q positive
24.0  3.1
14.5  2.5
18.1-30.0
9.4-19.5
.101
b 2 microglobulin, mg/L
3.5
>3.5
25.7  2.7
20.9  2.2
20.5-30.9
16.5-25.2
.230
Post-transplant PET
Negative
Positive
30.1  3.2
17.8  2.6
23.9-36.3
12.7-22.8
.008
APC in harvests
Absent
Present
24.0  1.9
14.4  3.3
20.4-27.7
8.0-20.8
.206
Pre-transplant response
<PR
PR
VGPR
CR
14.8  3.8
19.9  2.5
28.2  4.3
28.4  2.8
7.3-22.2
15.0-24.8
19.8-36.7
22.8-33.9
.021
Post-transplant response
<PR
PR
VGPR
CR
3.2  1.2
17.1  2.8
30.9  3.7
26.9  1.8
0.85-5.55
11.6-22.6
23.7-38.0
19.8-26.7
.001
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were signiﬁcantly associated with PFS. Post-ASCT PET(-) CR
had signiﬁcantly longer PFS than patients with PET(+) CR
(31.4  9.9 vs 18.4  3.5 months; p¼.029). In conclusion,
having an ISS-3 stage myeloma, pre and post-ASCT response
<VGPR had negative impact on PFS. Contamination of PBSC
harvests with APC was associated with shorter PFS. Our re-
sults also demonstrate the importance of achieving PET
negativity after transplantation. Thus, not only an immuno-
logical CR but also PET(-) CR should be achieved for long
term PFS.128
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Introduction: High-dose therapy with AutoHCT is a stan-
dard component of therapy for many patients with Hodgkin
(HL) and non-Hodgkin lymphoma (NHL). IPS is a known
toxicity of AutoHCT which can cause signiﬁcant morbidity
and mortality. The most common agent associated with IPS
has traditionally been high-dose BCNU (carmustine). Data on
incidence of IPS in recent era and its relation with condi-
tioning regimens are scarce.
Methods and Patients: Using the Center for International
Bone Marrow Transplant Registry (CIBMTR), we studied
4,573 patients with lymphoma who underwent AutoHCT
from 1995-2008 using the following conditioning regimens:
BEAM (n¼1730), CBVlow (n¼1249), CBVhigh (n¼604), BuCy
(n¼789), and CyTBI (n¼545). We investigated the reported
incidence of and explored clinical risk factors for its devel-
opment, including the dose of BCNU and its impact on
outcome (above vs. below 375 mg/m2 in CBV regimens). We
then analyzed the impact of IPS on outcomes including
transplant-related mortality (TRM), progression-free sur-
vival (PFS), and overall survival (OS). Use of different regi-
mens was as follows:
Results: The incidence of IPS by 1 year after AutoHCT was:
BEAM (3%), CBVlow (3%, HR 1.07 [0.72,1.60], p¼0.742), CBVhigh
(6%, HR 1.88 [1.24, 2.83], p¼0.003), BuCy (4%, HR 1.25 [0.82,1.92], p¼.30), and CyTBI (5%, HR 2.03 [1.30, 3.19], p¼.002).
Multivariate analysis showed the following risk factors for
developing IPS: 1) HL (HR 2.33, [1.68, 3.24], p < .001), 2)
female gender (HR 1.39 [1.05, 1.82], p¼.019), 3) chemo-
therapy-resistant disease at time of AutoHCT (HR 1.9 [1.29,
2.79], p¼.001), and age 55 (HR 1.54, [1.13, 2.09], p¼.006). In
the entire cohort, patients who developed IPS had a signiﬁ-
cantly higher rate of TRM (HR 4.02, [3.09, 5.24], p < .001),
shorter PFS (HR 1.82, [1.51, 2.20], p < .001), and shorter OS
(HR 2.46, [2.06, 2.94], p < .001).
Conclusion: IPS remains an important toxicity after AutoHCT
for patients with lymphoma and adversely effects overall
outcomes. Risk factors include higher doses of BCNU, TBI,
female gender, older age, chemotherapy resistant disease
and a diagnosis of HL. Investigation into strategies for the
prevention of IPS after ASCT is warranted.129
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The importance of optimal long term engraftment after
autologous stem cell transplantation is uncertain. We con-
ducted a retrospective analysis of long term engraftment in
patients who underwent autologous peripheral blood stem
cell transplant for non-Hodgkin lymphoma, Hodgkin lym-
phoma or multiple myeloma. Patients who relapsed or died
prior to assessment of long term engraftment at 1 year were
excluded. Optimal engraftment was deﬁned by NCI CTCAE
grade 1 criteria for cytopenias (ANC  1500/ml, platelets 
75000/ml, hemoglobin  10g/dL). 225 patients were iden-
tiﬁed with engraftment data at 1 year (92 NHL, 62 HL, 71
MM). Themedian follow-upwas 5.0 years for all patients (5.5
for living patients).
88% of patients achieved optimal engraftment at 1 year. The
median cell dose was 4.7 x10
ˇ
6 CD34+ cells/kg, and our
institutional minimum cell dose is 2 x10
ˇ
6 CD34+ cells/ kg.
CD34 cell dose  3 x10 ˇ6 CD34+ cells/kg and age < 60 were
predictive for optimal long term engraftment. Disease type,
gender, number of prior therapies and prior radiation ther-
apy were not predictive of achieving long term engraftment.
By landmark analysis at 1 year, optimal engraftment was not
predictive for progression free survival or overall survival in
all patients, although there was a trend for worse outcome
with poor engraftment in HL and NHL.
Incomplete long term engraftment after autologous trans-
plant is relatively rare with the most important predictors
identiﬁed as CD34 cell dose and age. For those patients who
survive one year, PFS and OS are not diminished afterward.130
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